Meconium aspiration syndrome

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

Retrieved on: 
Wednesday, April 3, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Abdomen, Research, Meconium, Meconium aspiration syndrome, Human, Congenital diaphragmatic hernia, Intubation, Pharmaceutical industry

Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.
  • Inspira aims to explore how this potential additional application of the INSPIRA ART100 device to provide neonates with vital respiratory support could replace the currently used mechanical ventilators.
  • "Inspira is dedicated to pushing the boundaries of medical technology to save and improve lives," remarked Dagi Ben-Noon, CEO of Inspira Technologies.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Global Meconium Aspiration Syndrome Market Report to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Health, Other Health, Review, Epidemiology, Growth–share matrix, Meconium aspiration syndrome, PESTLE, Research, Gaps, Report, Disease, Lists of people executed in the United States, SME, SWOT, Competition, Diagnosis, Awareness, Porter's five forces analysis, Pharmaceutical industry, Marketing

The "Meconium Aspiration Syndrome - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Meconium Aspiration Syndrome - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Meconium Aspiration Syndrome, historical and forecasted epidemiology as well as the Meconium Aspiration Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Meconium Aspiration Syndrome market report provides current treatment practices, emerging drugs, Meconium Aspiration Syndrome market share of the individual therapies, current and forecasted Meconium Aspiration Syndrome market Size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers current Meconium Aspiration Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Lundquist Institute Investigator Dr. Frans Walther Receives Grant to Develop an Aerosolized Lung Surfactant

Retrieved on: 
Wednesday, April 6, 2022
MAS, Hypoxia, Wasting, Bill & Melinda Gates Foundation, Mortality, IND, Pediatrics, Bill, Research, Doctor of Philosophy, CEO, Late preterm infant, MD, Goal, Institute, Infant, David Geffen School of Medicine at UCLA, Disease, Respiratory distress syndrome, UCLA, Meconium aspiration syndrome, RDS, Fatigue, Peptide, Apnea, Pharmaceutical industry

LOS ANGELES, April 6, 2022 /PRNewswire/ -- The Lundquist Institute's investigator Frans Walther, MD, PhD, has received a two-year grant from the Bill & Melinda Gates Foundation in the amount of $471,858.00 to support the development of a synthetic aerosolized lung surfactant and a non-invasive delivery device for use in infant respiratory distress syndrome (RDS), a significant cause of neonatal mortality and morbidity. Newborns experiencing RDS must dramatically increase the effort to take each breath, due to lack of adequate, naturally occurring surfactant production in their lungs. This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated. 

Key Points: 
  • This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated.
  • The target completion date for the funded research leading to the development of an aerosolized lung surfactant is March of 2024.
  • Our goal is to design, synthesize, and bring effective lung surfactant peptides, modeled after the sequence of human surfactant proteins B and C to clinical care.This grant will help us achieve these research goals."
  • "The Institute is grateful to the Bill & Melinda Gates Foundation for their support," said Dr. David Meyer, PhD, President and CEO of The Lundquist Institute.

Global Artificial Lung Devices Pipeline Insight and Competitive Landscape Report 2021: Comprehensive Insights About 20+ Companies and 23+ Pipeline Devices - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 22, 2021
Biotechnology, Health, Medical devices, Neonatology, Medical specialties, Health, Branches of biology, Syndromes, Artificial lung, Meconium aspiration syndrome, Lung, Meconium, Intensive care medicine

b'Artificial lung device is a prosthetic device works as an alternative to the biological lung.

Key Points: 
  • b'Artificial lung device is a prosthetic device works as an alternative to the biological lung.
  • It provides oxygenation of blood and removal of carbon dioxide from the blood.
  • Artificial lung devices are made of synthetic material that are connected to blood vessels through tubes and cannulas of silicone.\nThis segment of the artificial lung devices report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including latest news and press releases.
  • The report also provides list of major players involved in the pipeline product development.\nArtificial lung devices for decades have been used in newborns and children with lung failure, pneumonia, meconium aspiration syndrome and other conditions.